Akademik Veri Yönetim Sistemi
Bulletin of Gulhane Military Medical Academy, cilt.21, sa.1, ss.39-44, 1979 (Scopus)
The results of this rather large and long investigation on the relationship of HBAg and AFP during the course of chronic hepatitis and hepatoma can be summarised as follows: 1. To a certain extent (13% in chronic persistant hepatitis (CAH), 21% in cirrhosis) HBAg is responsible for the continuation of the disease in the given groups. 2. The percentages of HBAg does not present an important difference between the groups (p>0.05). This may suggest that from the very start the patients in whom, years later, hepatoma will develop are pre-selected. A thorough investigation may disclose these patients and their treatment may prevent the fatal outcome. According to the mean percentages, HBAg is responsible for the occurrence of hepatoma in 30% of the cases. As the result of hepatoma group indicates (50%), this percentage may be higher if better techniques can be applied. 3. The percentage of alpha feto-protein is 66% in the hepatoma group. It means that in a certain percentage factors other than HBAg are operating for the phenomenon of hepatoma. 4. HBAg is not continually present in the sera of patients; it may disappear from the sera and re-appear regardless of the presence of hepatitis-B antibody (HBAb). HBAb is not a prerequisite for the temporary disappearence of HBAg from the serum. 5. The high levels of AEP may eventually return to normal levels during the course of the chronic hepatitis and cirrhosis. In hepatoma, however, its presence is constant.